Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., May  18, 2020  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the sustained efficacy and longer-term safety of SPINRAZA in a broad range of patients with spinal muscular atrophy (SMA). These new data were selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting and will be available online via the 2020 AAN Science Highlights virtual platform.

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

JPMorgan Chase & Co

Kroger

PNC Financial Services

Suncor Energy

Berkshire Hathaway acquired $4 billion in equities during Q1, and these are the companies that were likely purchased.

5 Stocks Buffett Probably Bought in the First Quarter

Charter Communications

DaVita

Phillips 66

Forget the Berkshire Hathaway shareholder meeting -- this SEC filing is what you should be eyeing.

The All-Important Question Buffett Will Answer This Week

A delay in the regulatory submission of Alzheimer’s drug aducanumab weighed on the shares.

Why Biogen Shares Fell 6.18% in April

With Or Without Aducanumab, Biogen Is A Research Champion

The road to approval for aducanumab is far longer than it appears, if it even exists at all.

Has Biogen Found the Answer to Treating Alzheimer's?

Biogen May Have Dropped The Ball Trying To Resuscitate Aducanumab Filing

ACADIA Pharma

Amedisys

Boyd Gaming

Hill-Rom Hlds

Royal Caribbean Cruises

Teladoc

Thor Industries

UnitedHealth Group

Ventas

Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.

10 Stocks to Buy for an Aging Population

CAMBRIDGE, Mass., April  27, 2020  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion. The notes will mature as follows:

Biogen Prices $3.0 Billion of Senior Unsecured Notes

Booking Hlds

Blackrock Inc

Raytheon Technologies

VMware

Companies that have positive and steady net margins and operating margins are often good investments because they can return a solid profit to investors.

5 Undervalued Stocks With a Profitable Business

Gilead Sciences

Regeneron Pharmaceuticals

These are the health care stocks with the best value, fastest growth, and most momentum for May.

Top Health Care Stocks for May 2020

Intel

Investors are often wrong about how they trade mega cap stocks on their earnings headline. This created opportunities in INTC, IBM and BIIB.

3 Mega Cap Stocks Earnings Dips to Buy

Amgen

Incyte

Vertex Pharmaceuticals

Focus on Coronavirus Treatments to Boost Biotech Stocks

Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's investigational drug aducanumab will be delayed.

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Landbridge Co LLC

Snap

Thursday's big stock charts feature names that released noteworthy earnings data.
The post 3 Big Stock Charts for Thursday: Snap, Biogen, and L Brands appeared first on InvestorPlace.

3 Big Stock Charts for Thursday: Snap, Biogen, and L Brands

The biotech company announced that its FDA filing of aducanumab, a potential treatment for Alzheimer’s disease, will be delayed.

Biogen Reports First-Quarter Results, Shares Plunge 9.4%

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2020 Results - Earnings Call Transcript

When Biogen Inc. (NASDAQ: BIIB) reported its first-quarter financial results before the markets opened on Wednesday, the firm said that it had $9.14 in earnings per share (EPS) and $3.53 billion in revenue.

Does Biogen Stock Deserve More Credit for Q1 Earnings?

Biogen Inc. (NASDAQ: BIIB) released its earnings report for the first quarter on Wednesday that topped analysts’ estimates for earnings and revenue.

Biogen tanks 6% in premarket trading despite an upbeat financial report

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.

Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat

Shares of Biogen Inc. BIIB, -3.06% tumbled 6% in premarket trading on Wednesday even though the drugmaker beat earnings expectations for the quarter.

Biogen's stock falls 6% though earnings beat expectations

CAMBRIDGE, Mass., April  20, 2020  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today released its 2019 Corporate Responsibility Report that demonstrated continuous progress across several environmental, social and governance (ESG) metrics. The report outlines the company’s long-term commitment to corporate responsibility by taking a multi-stakeholder approach to business decisions, creating an inclusive culture, reducing its environmental footprint and increasing reporting transparency on ESG issues.   

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

A consortium in Cambridge, Massachusetts, will test patients who have recovered from the coronavirus to advance the search for vaccines and treatments.

Biogen Is Building a COVID-19 Biobank With the Broad Institute

Alexion Pharma

Johnson & Johnson

Novo Nordisk

Bio-Techne

Biotech and drug manufacturing companies with the strength to weather further coronavirus storms.

News for Biogen Stock (BIIB)